Disseminated infection due to Mycobacterium avium comemia, and increased survival were noted [14]. In that trial, however, 46% of all patients developed in vitro resistance to plex (MAC) was one of the earliest recognized complications clarithromycin, which was associated with a recrudescence of of AIDS [1, 2] . Prior to the availability of effective therapy, clinical symptoms and increases in the number of cfu of MAC survival among patients with disseminated MAC infection was isolated from the blood. In another series of clarithromycinshort (medians of 107 and 134 days in two published series containing regimens, of 56 patients whose bloodstreams were [3, 4] ). Using non-macrolide-containing regimens, some early cleared of MAC, 14 (25%) relapsed microbiologically, and 9 investigators of the treatment of MAC infection demonstrated of these 14 individuals were found to have developed infection short-term clinical and bacteriologic improvement [5 -8], while with clarithromycin-resistant MAC [15]. others showed improved short-term survival [9 -12].
Disseminated infection due to Mycobacterium avium comemia, and increased survival were noted [14] . In that trial, however, 46% of all patients developed in vitro resistance to plex (MAC) was one of the earliest recognized complications clarithromycin, which was associated with a recrudescence of of AIDS [1, 2] . Prior to the availability of effective therapy, clinical symptoms and increases in the number of cfu of MAC survival among patients with disseminated MAC infection was isolated from the blood. In another series of clarithromycinshort (medians of 107 and 134 days in two published series containing regimens, of 56 patients whose bloodstreams were [3, 4] ). Using non-macrolide-containing regimens, some early cleared of MAC, 14 (25%) relapsed microbiologically, and 9 investigators of the treatment of MAC infection demonstrated of these 14 individuals were found to have developed infection short-term clinical and bacteriologic improvement [5 -8] , while with clarithromycin-resistant MAC [15] . others showed improved short-term survival [9 -12] .
In 1993, the United States Public Health Service issued its A major advance in the therapy for MAC infection was the first guidelines for therapy for disseminated MAC infection recognition of the in vivo efficacy of clarithromycin [10, 13, in patients with HIV infection [16] . It recommended that all 14]. In a dose-ranging study of clarithromycin monotherapy treatment regimens include a macrolide and one to three addifor MAC bacteremia, diminished symptoms, reduced bactertional drugs to help prevent the development of resistance. Ethambutol, which has demonstrated in vivo activity against MAC [17] , was recommended as a second drug; several agents, including rifabutin, were listed as possible third and fourth Rifabutin, a semisynthetic rifamycin, has significant in vitro
Informed consent was obtained from all patients or guardians, and human activity against a number of mycobacteria, including Mycobacexperimentation guidelines of the U.S. Department of Health and Human Serterium tuberculosis and MAC [18] . Rifabutin is effective in vices and those of the participating institutions were followed in the conduct of this study.
prophylaxis for disseminated MAC infection in patients with
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in reducing the level of MAC bacteremia in several pilot studies
Financial support: Pharmacia & Upjohn, Inc. [5, 6] . In a 14-day trial of early bacteriologic activity, rifabutin of ethambutol and clofazamine alone [21] . In view of these available at week 16, however, were not counted as treatment responses. For patients who had negative cultures at week 16, promising findings, we conducted a prospective trial of treatment of MAC bacteremia, in which rifabutin or a matching a relapse was defined by any subsequent single blood culture with §10 cfu/mL or by any two positive cultures. For patients placebo was added to a regimen of clarithromycin and ethambutol.
without negative blood cultures but a §2-log 10 decrease in cfu/mL at week 16, a relapse was defined as an increase in cfu to a level õ2 log 10 below the baseline. A second primary Methods objective was to compare, at week 16, the abatement of clinical symptoms in each group. Study population. HIV-positive patients were eligible for the study if they were §12 years old and had a documented Bacteriologic evaluation. Blood cultures for MAC were processed at the National Jewish Center for Immunology and blood culture that was positive for MAC or a not-yet-speciated acid-fast bacillus, within 90 days prior to randomization. PaRespiratory Medicine, in Denver. The blood was concentrated, lysed, and plated, as previously described [22] . The organisms tients were also required to have two blood cultures performed within 14 days of randomization, and if neither was positive were quantified as cfu per mL of blood. Mycobacteria were identified with the AccuProbe (Gen-Probe, San Diego). Antimifor MAC, these patients were excluded from the study and not considered in the efficacy analysis. Patients were also required crobial susceptibility testing was performed with 7H12 broth, by means of a previously described radiometric method [23] . to have a minimum of two MAC-related symptoms -defined as fever, night sweats, fatigue, diarrhea, or abdominal painClarithromycin resistance was defined as an MIC of §32 mg/mL. within 14 days prior to randomization, or a §5% decrease in body weight during the 60 days prior to randomization.
Statistical analysis. The primary efficacy evaluation was based on the incidence of (and time to) bacteriologic response At baseline, patients needed serum aminotransferase levels õ101 the upper limit of normal, a bilirubin level õ31 the and negative cultures by week 16. Kaplan-Meier methodology was used to estimate the time-to-bacteriologic-response and upper limit of normal, a serum creatinine value £3.0 mg/dL, an absolute neutrophil count ú500/mm 3 , and a platelet count time-to-negative-blood-culture distributions for each treatment group. The log-rank test was then used to compare the esti-ú50,000/mm 3 . Patients were excluded who were pregnant or lactating, had a Karnofsky score of õ50, or had an estimated mated distributions. Chi-square statistics were used to make comparisons with respect to incidence at weeks 8 and 16. life expectancy of õ16 weeks. Patients were allowed to have received previous antimycobacterial therapy, but not within 7
Additional efficacy analyses were based on clinical symptoms associated with MAC bacteremia at weeks 8 and 16: days before the baseline blood cultures.
The protocol was reviewed and approved by each site's fever (absent or present), night sweats (£mild or úmild), and abdominal pain (£mild or úmild). institutional review board, and all patients or their guardians gave written informed consent.
Clinical symptoms and categorical baseline characteristics were examined with a x 2 test, and continuous baseline characStudy design. Patients were randomized to receive either rifabutin (300 mg once daily) or a matching placebo. All pateristic variables were assessed with a one-way ANOVA Ftest. tients received 500 mg of clarithromycin twice daily and 1,200 mg of ethambutol per day (patients weighing £50 kg received
The major analysis was an intention-to-treat analysis including all patients who had at least one positive blood culture for 800 mg/d). Patients were evaluated at weeks 2 and 4 and every 4 weeks thereafter until a common closing date. At each visit, MAC at baseline. A second, during-treatment analysis excluded patients who died within the first 15 days, received study medithe patient's history was recorded and a physical examination, complete blood cell count, and renal and liver function evaluacation for õ30 days, or had an interruption in study medication for ú30 days in the first 16 weeks, for reasons other than tions were performed. Two blood cultures for MAC were performed at weeks 8 and 16, and one blood culture was performed clinical failure or adverse event. The results of the duringtreatment analysis were similar to those of the intention-toat other visits. Patients could discontinue taking medications temporarily because of adverse effects or permanently because treat analysis and are not presented in this article. of recurrence of adverse effects, life-threatening toxicity, or the need for additional (nonstudy) antimycobacterial therapy.
Results The primary endpoint was the proportion of patients in each treatment group who, at week 16, had a bacteriologic response, From December 1993 to September 1996, patients were followed at 47 sites in the United States, Canada, and Mexico. defined as negative blood cultures for MAC or a §2-log 10 decrease in cfu per mL of blood. Patients who did not have a
The study cohort consisted of 198 patients for whom at least one blood culture was positive for MAC at baseline. The rifamicrobiologic response before week 16 and were not available at week 16 were counted as treatment failures; patients who butin arm of the study had 102 patients, and the placebo, 96; in addition, all patients received clarithromycin and ethambuhad a bacteriologic response before week 16 and were not / 9c65$$my20 04-06-99 08:12:38 cidas UC: CID Table 1 . Baseline characteristics of study participants. blood cultures was 55 days in the rifabutin group and 64 days tol. As shown in table 1, the patients were predominantly male, in the placebo group (log-rank P Å .32). sex with a male was the main HIV-risk behavior, and the mean As shown in table 3, fever was present in almost all patients CD4 cell count was 20/mm 3 . at baseline and responded similarly to the two regimens. Night The bacteriologic response to the two regimens was similar sweats and abdominal pain were more common in the placebo (table 2) . The groups were well matched at baseline: the median group at baseline and responded well to both regimens. Overall quantity of MAC in blood cultures was 18 cfu/mL for patients survival did not differ between the two groups (log-rank receiving rifabutin and 24 cfu/mL for patients assigned to pla-P Å .87). Patients receiving rifabutin had a median survival cebo (P Å .19). At 8 weeks, 58% of persons in each group of 398 days, and those in the placebo group had a median were found to have a bacteriologic response (P Å .95); by survival of 439 days. week 16, 63% of patients in the rifabutin group and 61% in Clarithromycin resistance was present at baseline in four the placebo group had responded (P Å .81). Of patients availpatients who received rifabutin and in three who received plaable for blood cultures at week 16, 73% in each group achieved cebo. Only one of these patients, who was in the placebo group, negative cultures for MAC. The median time to bacteriologic had a bacteriologic response. The development of clarithroresponse was 30 days in the rifabutin group and 56 days in the mycin resistance during therapy occurred in seven patients in placebo group (log-rank P Å .47). The median time to negative the rifabutin group and 10 in the placebo group. Of those patients who failed to achieve a bacteriologic response, six in the rifabutin group and four in the placebo group developed taking a study drug because of neutropenia. There was no * Eradication or a §2-log 10 decrese in cfu/mL, from baseline.
difference between the two study groups in terms of the number † Data represent the number of patients achieving end point / number of patients with end-point data available.
of patients developing other hematologic, renal, or liver abnor-/ 9c65$$my20 04-06-99 08:12:38 cidas UC: CID malities. Rash was reported for 16 patients receiving rifabutin daily dose of 300 mg of rifabutin was chosen to decrease the incidence of uveitis. This lower dose, however, may have and 19 receiving placebo (P Å .49), and uveitis was reported for 4 patients receiving rifabutin and 2 receiving placebo reduced the efficacy of the combination regimen. Another factor that may have lessened any additive benefit of rifabutin is (P Å .44).
the pharmacokinetic interaction of this agent with clarithromycin. Among HIV-negative patients treated for MAC pulmoDiscussion nary infection, the mean serum level of clarithromycin was 5.4 mg/mL among those receiving 500 mg of clarithromycin twice In this study, rifabutin, when added to a regimen of clarithromycin and ethambutol for the treatment of MAC bacteremia, daily, which was reduced to 2.0 mg/mL when rifabutin was added at a dosage of 600 mg daily [31] . In a pharmacokinetic did not improve the clearance of organisms, abatement of clinical symptoms, or survival rate. Among patients who did have study of HIV-positive patients, the addition of rifabutin at a dosage of 300 mg daily resulted in a 44% decrease in the a bacteriologic response, however, those who received rifabutin were less likely to develop in vitro resistance to clarithromycin.
area under the concentration-time curve of clarithromycin for persons receiving 500 mg of clarithromycin every 12 hours The importance of clarithromycin resistance has been demonstrated in this study as well as in other published series [14, [32] . Therefore, any potential gain in the clearance of MAC bacteremia in our study by the addition of rifabutin may have 15, 24, 25] . In this study, of seven persons who had clarithromycin resistance at baseline, only one had a treatment response been offset by a reduction in serum clarithromycin levels.
A number of studies have helped to clarify the initial treatat week 16. Furthermore, the only relapse occurred in a person who developed clarithromycin resistance during treatment. The ment regimen for AIDS patients with disseminated MAC infection. It is essential that a macrolide be included in the regimen, strong correlation between development of clarithromycin resistance and clinical failure was first demonstrated in a study of and some data support the use of azithromycin [33, 34] , although clarithromycin has been evaluated more extensively clarithromycin monotherapy for disseminated MAC infection [14] : in vitro resistance to clarithromycin developed in 46% of [13 -15, 24, 25, 28, 35] . In order to reduce the development of resistance to the macrolide, at least one additional drug must patients and was associated with recrudescence of symptoms and increases in cfu of MAC in the blood. be employed. Clofazimine has not been effective in preventing resistance [24, 25, 35] and may result in increased mortality More recently, May et al. compared a regimen of clarithromycin, rifabutin, and ethambutol with a regimen of clarithrowhen used in the treatment of MAC infection [35] . The most recent national guidelines state that in the treatment of MAC, mycin and clofazimine for the treatment of disseminated MAC infection [24] : resistance to clarithromycin developed in 23 clarithromycin should be used with either ethambutol or rifabutin or both [36] . patients, only two of whom were receiving the three-drug regimen; furthermore, the development of in vitro resistance was
We conclude that the regimen of clarithromycin and ethambutol was as effective as the same two drugs given with rifastrongly correlated with clinical failure. Additional evidence of the clinical importance of in vitro clarithromycin resistance butin. Since among those patients who responded bacteriologically there was a trend toward development of clarithromycin has been provided by Dube et al. [25] ; again, patients who developed in vitro resistance were likely to manifest clinical resistance in the two-drug group, one must question whether using rifabutin in addition to these two drugs would have longfailure.
Clarithromycin and rifabutin have been shown to be synerterm benefit. Clarithromycin and rifabutin may be equivalent to or better than clarithromycin and ethambutol, and the former gistic in vitro against MAC [26] . The clinical ability to use these drugs together, however, has been limited by drug toxiciregimen is currently being evaluated. Since rifabutin does not reduce azithromycin blood levels [37] , as it does clarithromycin ties, due in part to the pharmacokinetic interactions of the two drugs. In a study of prophylaxis for MAC infection, patients levels, the combination of azithromycin and rifabutin may have additive effects, as has been shown in a study of prophylaxis receiving rifabutin and clarithromycin had significantly more adverse events than patients taking either drug alone [27] . Of with these two drugs for MAC infection [38] . Therefore, the role of rifabutin for patients whose regimens contain azithroparticular significance was the development of uveitis in 8.5% of patients in the combination-treatment group. The occurrence mycin, as well as for persons infected with macrolide-resistant organisms, needs further investigation. of uveitis has also been reported when clarithromycin and rifabutin have been used together for the treatment of MAC infection in both HIV-positive and HIV-negative patients [24, 28, 29] .
